Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genprex, Inc. - Common Stock (NQ:GNPX)

0.2670 +0.0391 (+17.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Genprex, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted Fast Track Designation for Proprietary Immunogene Therapy from FDA
Via Investor Brand Network
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present in CEO Roadshow Webinar
Via Investor Brand Network
Genprex to Present in November CEO Roadshow Webinar
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Strengthens Management Team with Strategic Appointments
Via Investor Brand Network
Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer
From Genprex, Inc.
Via Business Wire
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Two Upcoming Investor Conferences
Via Investor Brand Network
Genprex to Participate in September Investor Conferences
From Genprex, Inc.
Via Business Wire
Genprex to Participate in a Monthly CEO Roadshow Webinar Series
From Genprex, Inc.
Via Business Wire
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review
From Genprex, Inc.
Via Business Wire
Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
From Genprex, Inc.
Via Business Wire
Genprex to Participate in Upcoming May Investor Conferences
From Genprex, Inc.
Via Business Wire
Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer
From Genprex, Inc.
Via Business Wire
Diamond Equity Research Emerging Growth Invitational Spring 2021 Virtual Conference
- One Day Conference May 11, 2021 - 25 Minute Presenting Time Slots From 8:30am to 1:25pm EST - Presentation Times and Links Distributed for All Presenting Companies - Investors Will Be Provided Time... 
From Diamond Equity Research LLC
Via AccessWire
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
From Genprex, Inc.
Via Business Wire
Genprex to Participate in CEO Roadshow Webinar Series
From Genprex, Inc.
Via Business Wire
Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
From Genprex, Inc.
Via Business Wire
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting
From Genprex, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.